OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy
OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has…
Genoscience Pharma receives FDA approval for Phase Ib/IIa study of GNS561 in liver cancer
Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing cancer treatment drugs, announces today that its most advanced…